These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1158 related articles for article (PubMed ID: 17762437)

  • 1. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small-cell lung cancer.
    Gridley DS; Bonnet RB; Bush DA; Franke C; Cheek GA; Slater JD; Slater JM
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):759-66. PubMed ID: 15465192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of late radiation fibrosis: a prospective study in non-small cell lung cancer.
    Mazeron R; Etienne-Mastroianni B; Pérol D; Arpin D; Vincent M; Falchero L; Martel-Lafay I; Carrie C; Claude L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):38-43. PubMed ID: 20171801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.
    Bral S; Duchateau M; Versmessen H; Engels B; Tournel K; Vinh-Hung V; De Ridder M; Schallier D; Storme G
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1352-9. PubMed ID: 20056350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
    Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
    Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
    Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
    Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
    Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan.
    Zhao L; Wang L; Ji W; Wang X; Zhu X; Hayman JA; Kalemkerian GP; Yang W; Brenner D; Lawrence TS; Kong FM
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1385-90. PubMed ID: 19231104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An accelerated radiotherapy scheme using a concomitant boost technique for the treatment of unresectable stage III non-small cell lung cancer.
    Izmirli M; Yaman F; Buyukpolat MY; Yoney A; Unsal M
    Jpn J Clin Oncol; 2005 May; 35(5):239-44. PubMed ID: 15886271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-volume image-guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas.
    Fukumoto S; Shirato H; Shimzu S; Ogura S; Onimaru R; Kitamura K; Yamazaki K; Miyasaka K; Nishimura M; Dosaka-Akita H
    Cancer; 2002 Oct; 95(7):1546-53. PubMed ID: 12237924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer.
    Zimmermann FB; Geinitz H; Schill S; Grosu A; Schratzenstaller U; Molls M; Jeremic B
    Lung Cancer; 2005 Apr; 48(1):107-14. PubMed ID: 15777977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
    Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
    Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.
    Baumann P; Nyman J; Hoyer M; Gagliardi G; Lax I; Wennberg B; Drugge N; Ekberg L; Friesland S; Johansson KA; Lund JS; Morhed E; Nilsson K; Levin N; Paludan M; Sederholm C; Traberg A; Wittgren L; Lewensohn R
    Radiother Oncol; 2008 Sep; 88(3):359-67. PubMed ID: 18768228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rhubarb extract on radiation induced lung toxicity via decreasing transforming growth factor-beta-1 and interleukin-6 in lung cancer patients treated with radiotherapy.
    Yu HM; Liu YF; Cheng YF; Hu LK; Hou M
    Lung Cancer; 2008 Feb; 59(2):219-26. PubMed ID: 17870203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
    Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer.
    Zhao L; Sheldon K; Chen M; Yin MS; Hayman JA; Kalemkerian GP; Arenberg D; Lyons SE; Curtis JL; Davis M; Cease KB; Brenner D; Anscher MS; Lawrence TS; Kong FM
    Lung Cancer; 2008 Feb; 59(2):232-9. PubMed ID: 17905467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients.
    Novakova-Jiresova A; Van Gameren MM; Coppes RP; Kampinga HH; Groen HJ
    Radiother Oncol; 2004 May; 71(2):183-9. PubMed ID: 15110452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
    De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.